-
Warning from the U.S. Food and Drug Administration About Fake Copies

On Monday, the U.S. Food and Drug Administration (FDA) warned consumers and pharmacies about the presence of counterfeit versions of the drug "Ozempic," which is used to treat type 2 diabetes, in the U.S. markets.
The agency clarified that these counterfeit products have entered the market through unlicensed distributors or vendors, raising concerns about patient safety. It added that it is working in collaboration with the drug's manufacturer, Novo Nordisk, to examine these products to determine whether they are safe for use.
In the United States, patients wishing to obtain "Ozempic" are required to present a valid prescription to licensed pharmacies, which are responsible for verifying the products for any signs of counterfeiting.
"Ozempic" is a glucagon-like peptide-1 receptor agonist aimed primarily at improving blood sugar control in adults with type 2 diabetes, as well as reducing the risk of major cardiovascular diseases.
"Ozempic" has also gained worldwide popularity as a weight-loss tool, with its manufacturer reporting nearly $17 billion in sales for the drug in 2024, according to a report by UPI news agency. The current warnings come at a time when the demand for this medication is increasing, highlighting the urgent need for quality monitoring and regulatory compliance in the pharmaceutical market.
You May Also Like
Popular Posts
Caricature
BENEFIT Sponsors BuildHer...
- April 23, 2025
BENEFIT, the Kingdom’s innovator and leading company in Fintech and electronic financial transactions service, has sponsored the BuildHer CityHack 2025 Hackathon, a two-day event spearheaded by the College of Engineering and Technology at the Royal University for Women (RUW).
Aimed at secondary school students, the event brought together a distinguished group of academic professionals and technology experts to mentor and inspire young participants.
More than 100 high school students from across the Kingdom of Bahrain took part in the hackathon, which featured an intensive programme of training workshops and hands-on sessions. These activities were tailored to enhance participants’ critical thinking, collaborative problem-solving, and team-building capabilities, while also encouraging the development of practical and sustainable solutions to contemporary challenges using modern technological tools.
BENEFIT’s Chief Executive Mr. Abdulwahed AlJanahi, commented: “Our support for this educational hackathon reflects our long-term strategic vision to nurture the talents of emerging national youth and empower the next generation of accomplished female leaders in technology. By fostering creativity and innovation, we aim to contribute meaningfully to Bahrain’s comprehensive development goals and align with the aspirations outlined in the Kingdom’s Vision 2030—an ambition in which BENEFIT plays a central role.”
Professor Riyadh Yousif Hamzah, President of the Royal University for Women, commented: “This initiative reflects our commitment to advancing women in STEM fields. We're cultivating a generation of creative, solution-driven female leaders who will drive national development. Our partnership with BENEFIT exemplifies the powerful synergy between academia and private sector in supporting educational innovation.”
Hanan Abdulla Hasan, Senior Manager, PR & Communication at BENEFIT, said: “We are honoured to collaborate with RUW in supporting this remarkable technology-focused event. It highlights our commitment to social responsibility, and our ongoing efforts to enhance the digital and innovation capabilities of young Bahraini women and foster their ability to harness technological tools in the service of a smarter, more sustainable future.”
For his part, Dr. Humam ElAgha, Acting Dean of the College of Engineering and Technology at the University, said: “BuildHer CityHack 2025 embodies our hands-on approach to education. By tackling real-world problems through creative thinking and sustainable solutions, we're preparing women to thrive in the knowledge economy – a cornerstone of the University's vision.”
opinion
Report
ads
Newsletter
Subscribe to our mailing list to get the new updates!